Four mechanistically distinct natural compounds — spermidine (autophagy via EP300 inhibition), fisetin (senolysis via PI3K/AKT and Bcl-2/Bcl-xL inhibition), berberine (metabolic regulation via AMPK activation plus gut microbiota remodeling), and urolithin A (mitophagy via PINK1/Parkin pathway) — are mapped against complementary hallmarks of aging in this narrative review. Berberine holds the largest clinical dataset of the four; urolithin A is accumulating registered human trial evidence; fisetin and spermidine have emerging but thinner human data.
The intellectual value here lies not in any single compound but in the mechanistic argument for combination: autophagy, senolysis, metabolic regulation, and mitophagy are upstream of multiple aging phenotypes, and hitting them simultaneously could theoretically produce additive or synergistic effects. That logic is compelling — but this remains a narrative review, meaning no original data, no head-to-head trials, and no confirmed synergy. Bioavailability is a persistent weak point for all four: fisetin's oral bioavailability is notoriously poor, berberine suffers P-glycoprotein-mediated efflux, and urolithin A production depends entirely on individual microbiome composition. For health-conscious adults, each compound individually has a plausible benefit-to-risk profile at studied doses. Combined formulations are commercially appealing but scientifically premature. Dedicated co-administration trials with aging biomarkers as endpoints are the necessary next step before any stack recommendation is warranted. Incremental, not paradigm-shifting.
